Sellas Life Sciences announces U.S. FDA granted RPDD to GPS

SELLAS Life Sciences announced that the U.S. Food and Drug Administration, FDA, has granted Rare Pediatric Disease Designation, RPDD, to Galinpepimut-S, GPS, an immunotherapeutic targeting Wilms Tumor-1, WT1, for the treatment of pediatric acute myeloid leukemia, AML. “GPS has already demonstrated promise in clinical settings for AML, and we believe its potential could extend to pediatric patients,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “Receiving RPDD from the FDA is another acknowledgment of the critical need for new treatment options for AML and our results in adult patients. In our Phase 2 trial in adult patients which included patients as young as 25, clinical benefits were significantly higher in younger patients, which was expected based on the mechanism of action of GPS that is mediated via the immune system that is generally better preserved in younger patients, and even more so in children. With both of our development candidates, GPS and SLS009, now granted RPDD for AML, this recognition further reinforces our commitment to delivering potential new therapies to children affected by this challenging condition.”